 It was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance.It was approved for medical use by the FDA in October 2007, EMA in September 2009, MHRA in November 2007, and TGA in January 2008.In the United Kingdom it costs the NHS £2,432.85 per month as of 2018.